Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Radiotherapy in Oligometastatic Nasopharyngeal Carcinoma
NCT05147844Phase 2Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Xinqiao Hospital. Primary endpoint: 1-year Progression-Free Survival Rate. Started Mar 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05147844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147844.